$3.62
Live
3.87%
Downside
Day's Volatility :5.43%
Upside
1.63%
44.61%
Downside
52 Weeks Volatility :67.29%
Upside
40.95%
Period | Sutro Biopharma Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.52% | 3.6% | 0.0% |
6 Months | -1.06% | 10.2% | 0.0% |
1 Year | 26.44% | 19.6% | 0.0% |
3 Years | -80.11% | 16.8% | -23.0% |
Market Capitalization | 304.1M |
Book Value | $1.86 |
Earnings Per Share (EPS) | -1.78 |
Wall Street Target Price | 12.0 |
Profit Margin | -73.48% |
Operating Margin TTM | -189.39% |
Return On Assets TTM | -13.91% |
Return On Equity TTM | -81.1% |
Revenue TTM | 169.4M |
Revenue Per Share TTM | 2.56 |
Quarterly Revenue Growth YOY | 146.9% |
Gross Profit TTM | -42.5M |
EBITDA | -99.1M |
Diluted Eps TTM | -1.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.95 |
EPS Estimate Next Year | -2.99 |
EPS Estimate Current Quarter | -0.79 |
EPS Estimate Next Quarter | -0.89 |
What analysts predicted
Upside of 231.49%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 38.4M | ↓ 25.75% |
Net Income | -35.3M | ↑ 79.38% |
Net Profit Margin | -91.93% | ↓ 53.88% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 42.7M | ↑ 11.24% |
Net Income | -55.7M | ↑ 57.84% |
Net Profit Margin | -130.44% | ↓ 38.51% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 42.7M | ↓ 0.03% |
Net Income | -36.2M | ↓ 35.05% |
Net Profit Margin | -84.75% | ↑ 45.69% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 61.9M | ↑ 44.84% |
Net Income | -108.7M | ↑ 200.17% |
Net Profit Margin | -175.62% | ↓ 90.87% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 67.8M | ↑ 9.52% |
Net Income | -119.2M | ↑ 9.69% |
Net Profit Margin | -175.89% | ↓ 0.27% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 153.7M | ↑ 126.84% |
Net Income | -106.8M | ↓ 10.41% |
Net Profit Margin | -69.47% | ↑ 106.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.7M | ↑ 46.83% |
Net Income | -50.1M | ↑ 34.93% |
Net Profit Margin | -394.9% | ↑ 34.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.4M | ↓ 17.85% |
Net Income | -38.5M | ↓ 23.03% |
Net Profit Margin | -370.0% | ↑ 24.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.9M | ↑ 62.54% |
Net Income | -49.3M | ↑ 27.93% |
Net Profit Margin | -291.21% | ↑ 78.79% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 113.7M | ↑ 571.95% |
Net Income | 31.1M | ↓ 163.03% |
Net Profit Margin | 27.32% | ↑ 318.53% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↓ 88.56% |
Net Income | -58.2M | ↓ 287.39% |
Net Profit Margin | -447.52% | ↓ 474.84% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 25.7M | ↑ 97.62% |
Net Income | -48.0M | ↓ 17.51% |
Net Profit Margin | -186.8% | ↑ 260.72% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 223.1M | ↑ 447.33% |
Total Liabilities | 91.6M | ↓ 38.84% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 156.4M | ↓ 29.92% |
Total Liabilities | 58.6M | ↓ 36.05% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 394.1M | ↑ 152.04% |
Total Liabilities | 62.1M | ↑ 5.94% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 341.4M | ↓ 13.37% |
Total Liabilities | 88.8M | ↑ 43.15% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 406.9M | ↑ 19.2% |
Total Liabilities | 189.9M | ↑ 113.74% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 470.7M | ↑ 15.68% |
Total Liabilities | 321.1M | ↑ 69.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 358.0M | ↓ 12.02% |
Total Liabilities | 172.6M | ↓ 9.11% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 464.9M | ↑ 29.85% |
Total Liabilities | 310.2M | ↑ 79.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 431.7M | ↓ 7.13% |
Total Liabilities | 319.4M | ↑ 2.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 470.7M | ↑ 9.03% |
Total Liabilities | 321.1M | ↑ 0.53% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 403.4M | ↓ 14.3% |
Total Liabilities | 305.4M | ↓ 4.89% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 489.0M | ↑ 21.23% |
Total Liabilities | 336.9M | ↑ 10.31% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 12.7M | ↓ 134.21% |
Investing Cash Flow | -80.2M | ↓ 345.97% |
Financing Cash Flow | 170.8M | ↑ 1066.64% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -65.0M | ↓ 612.68% |
Investing Cash Flow | -51.1M | ↓ 36.24% |
Financing Cash Flow | -4.2M | ↓ 102.45% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -67.8M | ↑ 4.27% |
Investing Cash Flow | 604.0K | ↓ 101.18% |
Financing Cash Flow | 269.2M | ↓ 6535.16% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -81.7M | ↑ 20.47% |
Investing Cash Flow | -97.3M | ↓ 16211.75% |
Financing Cash Flow | 3.3M | ↓ 98.79% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.5M | ↓ 104.35% |
Investing Cash Flow | -35.0M | ↓ 64.01% |
Financing Cash Flow | 48.3M | ↑ 1383.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -61.0M | ↑ 155.58% |
Investing Cash Flow | 67.5M | ↓ 278.06% |
Financing Cash Flow | 8.8M | ↓ 28.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -31.2M | ↓ 48.85% |
Investing Cash Flow | 66.2M | ↓ 1.92% |
Financing Cash Flow | 137.7M | ↑ 1471.83% |
Sell
Neutral
Buy
Sutro Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sutro Biopharma Inc | 3.9% | -1.06% | 26.44% | -80.11% | -65.97% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sutro Biopharma Inc | NA | NA | NA | -2.95 | -0.81 | -0.14 | NA | 1.86 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sutro Biopharma Inc | Buy | $304.1M | -65.97% | NA | -73.48% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Sutro Biopharma Inc
Revenue is up for the last 2 quarters, 13.00M → 25.70M (in $), with an average increase of 49.4% per quarter
Netprofit is up for the last 2 quarters, -58.21M → -48.01M (in $), with an average increase of 21.2% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 66.0%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 124.9%
Suvretta Capital Management, LLC
BlackRock Inc
Point72 Asset Management, L.P.
Millennium Management LLC
Vanguard Group Inc
MPM Oncology Impact Management LP
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Organization | Sutro Biopharma Inc |
Employees | 304 |
CEO | Mr. William J. Newell J.D. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.62
-2.95%
Invesco Bulletshares 2025 Hi
$3.62
-2.95%
Schwab International Dividend Equity Etf
$3.62
-2.95%
Blockchain Coinvestors Acquisition Corp.
$3.62
-2.95%
Allgiant Travel Company
$3.62
-2.95%
Rogers Corp
$3.62
-2.95%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.62
-2.95%
Iheartmedia
$3.62
-2.95%
Lightpath Technologies Inc
$3.62
-2.95%